JP2023537316A - 抗コネキシン抗体製剤 - Google Patents

抗コネキシン抗体製剤 Download PDF

Info

Publication number
JP2023537316A
JP2023537316A JP2023506315A JP2023506315A JP2023537316A JP 2023537316 A JP2023537316 A JP 2023537316A JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023537316 A JP2023537316 A JP 2023537316A
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical formulation
seq
histidine
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506315A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022026914A5 (https=
JP2023537316A5 (https=
Inventor
ヤンフェン ジャン，
Original Assignee
アラマブ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラマブ セラピューティクス， インコーポレイテッド filed Critical アラマブ セラピューティクス， インコーポレイテッド
Publication of JP2023537316A publication Critical patent/JP2023537316A/ja
Publication of JPWO2022026914A5 publication Critical patent/JPWO2022026914A5/ja
Publication of JP2023537316A5 publication Critical patent/JP2023537316A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2023506315A 2020-07-31 2021-07-30 抗コネキシン抗体製剤 Pending JP2023537316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059502P 2020-07-31 2020-07-31
US63/059,502 2020-07-31
PCT/US2021/044043 WO2022026914A1 (en) 2020-07-31 2021-07-30 Anti-connexin antibody formulations

Publications (3)

Publication Number Publication Date
JP2023537316A true JP2023537316A (ja) 2023-08-31
JPWO2022026914A5 JPWO2022026914A5 (https=) 2024-08-07
JP2023537316A5 JP2023537316A5 (https=) 2024-08-07

Family

ID=80002768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506315A Pending JP2023537316A (ja) 2020-07-31 2021-07-30 抗コネキシン抗体製剤

Country Status (9)

Country Link
US (2) US11912764B2 (https=)
EP (1) EP4188544A4 (https=)
JP (1) JP2023537316A (https=)
KR (1) KR20230042744A (https=)
CN (1) CN116234576A (https=)
AU (1) AU2021316119A1 (https=)
CA (1) CA3190474A1 (https=)
IL (1) IL300245A (https=)
WO (1) WO2022026914A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095897A1 (en) * 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
US20250277017A1 (en) * 2022-04-29 2025-09-04 Board Of Regents, The University Of Texas System Compositions and methods for treating eye diseases
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis
WO2025038635A1 (en) * 2023-08-14 2025-02-20 Alamab Therapeutics, Inc. Method of treating stroke
US20260103512A1 (en) * 2024-05-24 2026-04-16 Alamab Therapeutics, Inc. Method of treating bone cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509283A (ja) * 2016-02-26 2019-04-04 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用
WO2019195273A1 (en) * 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
JP2020509031A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 抗ｒｓｖモノクローナル抗体製剤
WO2020163353A1 (en) * 2019-02-04 2020-08-13 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073629B1 (ko) 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
EP1871806A2 (en) * 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
US20190010224A1 (en) * 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
EP3419599A4 (en) * 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
WO2017190152A1 (en) 2016-04-29 2017-11-02 Ocunexus Therapeutics, Inc. Sustained release drug delivery devices
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP2020531523A (ja) * 2017-08-25 2020-11-05 オメロス コーポレーション 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法
US11274150B2 (en) * 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
KR20220113355A (ko) * 2019-10-02 2022-08-12 알라맵 테라퓨틱스, 인크. 항-코넥신 항체 제제
WO2022026914A1 (en) 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509283A (ja) * 2016-02-26 2019-04-04 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用
JP2020509031A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 抗ｒｓｖモノクローナル抗体製剤
WO2019195273A1 (en) * 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2020163353A1 (en) * 2019-02-04 2020-08-13 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof

Also Published As

Publication number Publication date
EP4188544A4 (en) 2024-09-11
IL300245A (en) 2023-03-01
US20240309085A1 (en) 2024-09-19
US20220033492A1 (en) 2022-02-03
AU2021316119A1 (en) 2023-03-02
EP4188544A1 (en) 2023-06-07
CN116234576A (zh) 2023-06-06
US11912764B2 (en) 2024-02-27
CA3190474A1 (en) 2022-02-03
WO2022026914A1 (en) 2022-02-03
KR20230042744A (ko) 2023-03-29

Similar Documents

Publication Publication Date Title
JP2023537316A (ja) 抗コネキシン抗体製剤
US10588976B2 (en) Anti-CD40 antibody formulation
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
KR102109053B1 (ko) 안정한 수성 항체 제제
JP7805289B2 (ja) 抗コネキシン抗体製剤
CN116327917A (zh) 高度浓缩的低粘度masp-2抑制性抗体制剂、试剂盒和方法
EP2094729A1 (en) Abeta antibody parenteral formulation
CN113453719A (zh) 包含抗cd47抗体的制剂及其制备方法和用途
JP2018531980A (ja) 抗ｄ因子抗体製剤
WO2022000046A1 (en) High concentration formulation of factor xii antigen binding proteins
CN110536698B (zh) 重组单克隆抗TNFα抗体的水性药用组合物
JP2022544850A (ja) 抗ｐｄ１抗体プロルゴリマブの水性医薬組成物およびその使用
HK40077586A (en) Anto-connexin antibody formulations
EP4548931A1 (en) Anti-pcsk9 antibody preparation and use thereof
HK40093811A (zh) 高度浓缩的低粘度masp-2抑制性抗体制剂、试剂盒和方法
HK40093808A (zh) 高度浓缩的低粘度masp-2抑制性抗体制剂、试剂盒和方法
US20250108109A1 (en) Formulations comprising fab-peg
HK40096813A (zh) 抗pcsk9抗体的制剂及其应用
CN121490076A (zh) 一种稳定的抗人masp2单克隆抗体制剂
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
HK40010132A (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNFα

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260408